K562/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate

BD Smith, YL Kasamon, J Kowalski, C Gocke… - Clinical Cancer …, 2010 - AACR
Purpose: Chronic myeloid leukemia (CML) can be responsive to T-cell–mediated immunity.
K562/granulocyte macrophage-colony stimulating factor (GM-CSF) is a GM-CSF producing …
被引用次数：125 相关文章

[引用][C] K562/GM-CSF Immunotherapy Reduces Tumor Burden in Chronic Myeloid Leukemia Patients with Residual Disease on Imatinib Mesylate

BD SMITH, YL KASAMON… - Clinical cancer …, 2010 - pascal-francis.inist.fr
K562/GM-CSF Immunotherapy Reduces Tumor Burden in Chronic Myeloid Leukemia
Patients with Residual Disease on Imatinib Mesylate CNRS Inist Pascal-Francis CNRS …
[HTML] nih.gov

[HTML][HTML] K562/GM-CSF Immunotherapy Reduces Tumor Burden in Chronic Myeloid Leukemia Patients with Residual Disease on Imatinib Mesylate

BD Smith, YL Kasamon, J Kowalski… - … cancer research: an …, 2010 - ncbi.nlm.nih.gov
Purpose CML can be responsive to T cell mediated immunity. K562/GM-CSF is a GM-CSF
producing vaccine derived from a CML cell line that expresses several CML associated …

K562/GM-CSF Immunotherapy Reduces Tumor Burden in Chronic Myeloid Leukemia Patients with Residual Disease on Imatinib Mesylate

BD Smith, YL Kasamon, J Kowalski, C Gocke… - Clinical Cancer …, 2010 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: p> Purpose: Chronic myeloid leukemia (CML) can
be responsive to T-cell–mediated immunity. K562/granulocyte macrophage-colony …

K562/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate

BD Smith, YL Kasamon, J Kowalski… - Clinical Cancer …, 2010 - pure.johnshopkins.edu
Purpose: Chronic myeloid leukemia (CML) can be responsive to T-cell-mediated immunity.
K562/granulocyte macrophage-colony stimulating factor (GM-CSF) is a GM-CSF producing …

K562/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate.

BD Smith, YL Kasamon, J Kowalski… - … Cancer Research: an …, 2010 - europepmc.org
Purpose Chronic myeloid leukemia (CML) can be responsive to T-cell-mediated immunity.
K562/granulocyte macrophage-colony stimulating factor (GM-CSF) is a GM-CSF producing …

K562/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate

BD Smith, YL Kasamon, J Kowalski… - … : an official journal …, 2010 - pubmed.ncbi.nlm.nih.gov
Purpose Chronic myeloid leukemia (CML) can be responsive to T-cell-mediated immunity.
K562/granulocyte macrophage-colony stimulating factor (GM-CSF) is a GM-CSF producing …

[引用][C] K562/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate

S BD - Clin Cancer Res., 2010 - cir.nii.ac.jp
K562/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients
with residual disease on imatinib mesylate | CiNii Research CiNii 国立情報学研究所 学術情報 …

[引用][C] K562/GM-CSF Immunotherapy Reduces Tumor Burden in Chronic Myeloid Leukemia Patients with Residual Disease on Imatinib Mesylate

BD SMITH, YL KASAMON… - Clinical …, 2010 - American Association for Cancer …